Here we demonstrate that immunogenic modulation promoted by these HDAC inhibitors is a consequence of direct target inhibition, as silencing HDAC1 in tumor targets increases their sensitivity to CTL killing to the same extent as pharmacological inhibition with vorinostat, with no additive effect of vorinostat observed in targets with silenced HDAC1 (Figure 3). Here, HDAC9 is linked to neoplasm.